Teva Pharmaceutical Industries Ltd. ADR-1.87% $19.76B ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to launch the first treatment for the relentless itching experienced by some ...

GSK has made another trip to China to build out its antibody-drug conjugate (ADC) pipeline, returning with an option on a preclinical Duality Biologics candidate that could ultimately cost the Big ...

LONDON — A blood cancer treatment from GSK helped patients live longer in a pivotal trial, a significant finding as the once-withdrawn drug mounts a comeback. In the study, a treatment ...

GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents, the ...

But the main game is to find enough winners to more than offset the losers So we wouldn't blame long term GSK plc (LON:GSK) shareholders for doubting their decision to hold, with the stock down 38 ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

When GSK and Zhifei joined hands more than a year ago, Zhifei said it would purchase a minimum of 20.6 billion yuan worth of Shingrix to sell in China over just three years from 2024 to 2026.

After hours: 7:57:00 p.m. EST ...